A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA).
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Ferumoxytol (Primary) ; Ferric carboxymaltose
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Registrational
- Acronyms FIRM
- Sponsors AMAG Pharmaceuticals
- 14 Nov 2017 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Results presented in an AMAG Pharmaceuticals Media Release.
- 06 Nov 2017 According to an AMAG Pharmaceuticals media release, data were presented at the 2017 American Society of Nephrology (ASN) annual meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History